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Collecting duct carcinoma was recognized as a distinctive type of renal cell car-cinoma in 1986 by Fleming and Lewi1,2 on the basis of a description of 6 cases of
high-grade, invasive adenocarcinoma, arising in the renal collecting system and
showing characteristic tubulopapillary growth associated with prominent stromal
reaction.2–4 Review of published series of collecting duct carcinomas shows a male
predominance of B2:1, a laterality favoring the right kidney of B2:1, and an ag-
gressive clinical course with survival of B50% at 3 years.5–7 Recent eﬀorts have
addressed the diﬃculty of distinction of collecting duct carcinoma from urothelial
carcinoma of the upper tract, including by the use of immunohistochemistry.8,9 To
encourage uniformity in this diagnosis, the newly reported International Society of
Urological Pathology (ISUP) Vancouver Classiﬁcation10 emphasizes diagnostic
criteria, including the following: “(1) at least some of the lesion involves the me-
dullary region; (2) there is a predominant formation of tubules; (3) a desmoplastic
stromal reaction should be present; (4) cytologic features are high grade; (5) growth
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pattern is inﬁltrative; and (6) there is an absence of
other typical renal cell carcinoma subtypes or urothelial
carcinoma.”
Renal medullary carcinoma was ﬁrst described by
Davis et al11 in 1995, on the basis of an observation of 34
cases arising, with a single exception, in individuals with
sickle cell trait. Recent series conﬁrm that this poorly
diﬀerentiated adenocarcinoma occurs most frequently
among the young, with the mean age in the third decade,
marked male predominance (>2:1), right-sided laterality
(>2:1), high stage at presentation, including nodal or
visceral metastasis in >50% of cases, and exceptionally
poor survival.7,12–14 Evidence of sickle cell trait, disease, or
related hemoglobinopathy, whether by history taking, he-
moglobin electrophoresis, or histologic identiﬁcation of
drepanocytes, is apparent in the vast majority of cas-
es.7,12–16 Histologic studies have characterized the high-
grade, poorly diﬀerentiated appearance of the invading
glands in medullary carcinoma, which frequently show a
reticular and cribriform appearance and inﬁltrative growth
eliciting desmoplasia and stromal inﬂammation; a subset of
cases may also show rhabdoid cytomorphology or tubular/
tubulopapillary architecture.7,14,16 Renal medullary carci-
nomas show immunohistochemical loss of expression of the
nuclear transcriptional regulator SMARCB1 (INI1), en-
coded on chromosome 22.16–19 Molecular studies have
correlated this ﬁnding to loss of heterozygosity16 or hemi-
zygous deletions19 at the SMARCB1 locus, although loss of
chromosome 22 has also been observed.12 Recent data
suggest that acquisition of expression of the stem cell
marker, POU5F1 (herein, OCT3/4), may also be diagnos-
tically helpful.15 For that matter, infrequent cases of sickle
cell trait–associated renal carcinoma, showing amplification
of the kinase ABL,20 have been identified, as have cases with
fusions between the kinase, ALK, and the gene VCL,21–23
which are considered an “Emerging/Provisional New
Tumor Entity” under the ISUP Vancouver Classification.
Although authors have postulated a relationship between
renal medullary carcinoma and collecting duct carcino-
ma,2,3,7 the question of whether or not the specific clinical
setting of sickle cell trait or disease is requisite to make the
diagnosis was not addressed in the ISUP Vancouver Clas-
sification of Renal Neoplasia itself10 or at the consensus
conference24 held concurrently at the 2013 Meeting of the
United States and Canadian Academy of Pathology.
We were spurred to revisit this issue by a case we
reviewed in consultation, of a high-grade adeno-
carcinoma, conﬁned to the left kidney without metastasis
at the time of resection, which arose in a white female in
her twenties conﬁrmed to have normal hemoglobin by
electrophoresis. The morphology was of a high-grade,
widely inﬁltrative adenocarcinoma, centered in the col-
lecting system, with variable, tubular, nested, and cribri-
form architecture, sclerosing to myxoid stromal reaction,
and perineural invasion (Figs. 1A–D). The lesion had
expression of keratins and PAX8, consistent with a renal
primary (not shown). Nuclear expression of SMARCB1
was uniformly lost, whereas OCT3/4 showed a subset of
positive nuclei (Figs. 1D–F). As the World Health Or-
ganization4 and ISUP classifications10 do not address
how to classify such a case, we informally surveyed a
panel of 20 experts, leaders, and prior collaborators in
kidney tumor pathology as to their diagnostic approach
to such a case. We asked how they would diagnose such a
case, and we asked whether a relevant hemoglobinopathy
was an obligate diagnostic criterion for medullary
carcinoma or whether immunomorphology was sufficient
for the diagnosis.11 We tabulated deidentified responses,
revealing the following breakdown by diagnosis: renal
medullary carcinoma (30%), collecting duct carcinoma
(15%), renal cell carcinoma, unclassified (15%), ambig-
uous/descriptive diagnosis (30%), or insufficient experi-
ence (10%). Eighteen colleagues addressed our query
regarding whether, to them, sickle cell trait was generally
a required diagnostic criterion, with 44% in the affirma-
tive, and 56% in the negative. We conclude that a con-
sensus does not exist as to whether evidence of sickle cell
trait or disease is a required criterion for renal medullary
carcinoma diagnosis.
We submit that either position is eminently argu-
able. The trend in pathology is increasingly to guide or
sometimes establish diagnosis by molecular status, a de-
velopment reﬂected by the ISUP Vancouver Classiﬁcation
that deﬁnes entities such as Xp11 or t(6;11) transloca-
tion renal cell carcinomas by translocation status or
hereditary leiomyomatosis renal cell carcinoma syndrome–
associated renal cell carcinoma by fumarate hydratase
mutation status.10 Whether collecting duct and medullary
carcinomas are a spectrum, with the medullary variant at
the more aggressive end, has been extensively de-
bated.2,3,7,11,25,26 Thus, it is very reasonable to consider
defining renal medullary carcinoma as a variant of col-
lecting duct carcinoma showing loss of expression of
SMARCB19,16,17,19 or even induction of OCT3/415 by
immunohistochemistry.
In contrast, the argument to separate renal medul-
lary carcinoma from collecting duct carcinoma and deﬁne
it by the clinical setting dates back to the original Davis
et al11 description, literally as a “sickle cell nephropathy,”
deliberately separating it from collecting duct carcinoma.
This observation continues through larger series12,16 and
interinstitutional clinicopathologic comparisons of these
carcinomas,7 verifying the aggressiveness of renal me-
dullary carcinoma. Against deﬁnition of renal medullary
carcinoma by loss of SMARCB1 nuclear immuno-
reactivity, recent experience identiﬁes focal/weak ex-
pression of this marker in 2/6 collecting duct carcinomas
in 1 study9 and complete (15%) or decreased (another
15%) expression, with no diﬀerence in survival by
SMARCB1 expression, in another cohort of 20 cases of
collecting duct carcinoma.25 Our recent case, which would
be renal medullary carcinoma by a SMARCB1 expression
loss criterion or collecting duct carcinoma by clinical
setting criterion, underscores the problem. Our case oc-
curred in a patient of the less frequent sex and laterality of
kidney for either tumor type, while showing lack of the
locally advanced or metastatic disease at presentation
more characteristic of medullary carcinoma.
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Thus, we propose that nearly 30 years after recog-
nition of collecting duct carcinoma and 20 years after
renal medullary carcinoma, it is time to begin to address
this conundrum, even if provisionally, in advance of re-
vision of the World Health Organization “Blue Book.”4
Although further studies are necessary to understand the
relationship between these cancers, we recommend that
collecting duct carcinoma be deﬁned as proposed in the
ISUP Vancouver Classiﬁcation and outlined above.10 For
renal medullary carcinoma, we propose that it be deﬁned
as originally proposed by Davis and colleagues, on the
basis of both appropriate histology and evidence of sickle
cell trait or disease, preferably including hemoglobin
electrophoresis. Finally, to address the dilemma of cases
of high-grade renal adenocarcinomas showing morpho-
logy, immunophenotypic, or molecular features charac-
teristic of medullary carcinoma but in a patient without
evidence of hemoglobinopathy, we propose the term un-
classiﬁed renal cell carcinoma with medullary phenotype.
With this diagnosis, we recommend inclusion of com-
ments with respect to the (1) clinical setting, that is, lack of
evidence of sickle cell disease, trait, or related hemoglo-
binopathy, and (2) description of features that are present
(morphology, eg, cribriform, myxoid, reticular, rhabdoid;
immunohistochemistry, including any data for OCT3/4,
SMARCB1, or even ALK; and molecular, including in-
creasingly available genetic or sequencing data). This ap-
proach will allow prospective accrual of these data points
and will help patients, clinicians, and researchers under-
stand our diagnoses going forward. With emerging tech-
nologies as tools, coupled with standardized terminology,
we may be able to achieve meaningful deﬁnitional criteria
regarding these tumors when we revisit “Vancouver.”
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